Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma
LARKSPUR, Calif.–(BUSINESS WIRE)–#GBMAGILE–Global Coalition for Adaptive Research (GCAR), Sponsor of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) master protocol, announced that regorafenib has completed enrollment and follow-up in GBM AGILE. Enrollment for the arm was stopped after an interim analysis showed a low probability of sufficient improvement in overall survival as compared with randomized … [Read more…]
